Nutritional and Pharmacological Strategies to Regulate Microglial Polarization in Cognitive Aging and Alzheimer's

Emiliano Peña-Altamira1, Sabrina Petralla1, Francesca Massenzio1

  • 1Department of Pharmacy and Biotechnology, University of BolognaBologna, Italy.

Insights

Microglia polarization, the brain

Area of Science:

  • Neuroscience and Immunology
  • Focuses on brain immune cells (microglia) and their role in aging and neurodegenerative diseases.

Background:

  • Microglia, the brain's immune cells, exhibit polarization into M1 (pro-inflammatory) and M2 (neuroprotective) phenotypes.
  • Microglia polarization is crucial in brain aging, neuroinflammation, and neurodegenerative diseases like Alzheimer's disease (AD).
  • Dysfunctional microglia and senescence are linked to cognitive decline in aging and neuropathology.

Purpose of the Study:

  • To review current therapeutic strategies targeting microglia polarization for cognitive aging and AD.
  • To explore pharmacological and nutritional approaches that modulate microglia phenotypes.
  • To propose a combined therapeutic strategy for synergistic effects.

Main Methods:

  • Review of recent scientific literature on microglia polarization.
  • Analysis of pharmacological agents targeting molecular pathways (e.g., GSK3β, AMPK, HDACs).
  • Evaluation of nutritional compounds (e.g., polyphenols) and their anti-inflammatory effects on microglia.

Main Results:

  • Microglia polarization significantly influences cognitive function and disease progression.
  • Pharmacological and nutritional interventions show promise in shifting microglia towards a neuroprotective M2 phenotype.
  • Existing approaches require further development and validation.

Conclusions:

  • Modulating microglia polarization is a key therapeutic target for age-related cognitive decline and AD.
  • Combining pharmacological and nutritional strategies may offer synergistic benefits.
  • Further research is needed to optimize these immunomodulatory approaches for clinical application.

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
735
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K